Exelixis (EXEL) Deferred Taxes (2018 - 2022)
Exelixis (EXEL) posted quarterly Deferred Taxes of $60.4 million for Q4 2022, up 526.14% year-over-year from $9.6 million in Q4 2021, and up 294.03% quarter-over-quarter from $15.3 million in Q3 2022.
Analysis
Exelixis (EXEL) Deferred Taxes (2018 - 2022) Analysis & Trends
Exelixis' Deferred Taxes history runs 5 years deep, the most recent figure standing at $60.4 million for Q4 2022.
- In Q4 2022, Deferred Taxes rose 526.14% year-over-year to $60.4 million; the TTM figure through Mar 2023 stood at $75.7 million (up 216.01% YoY), while the FY2026 annual figure was -$126.2 million, down 312.31% from the prior year.
- Deferred Taxes for Q4 2022 stood at $60.4 million, up from $15.3 million in the prior quarter.
- The five-year high for Deferred Taxes was $244.1 million in Q4 2018, with the low at -$71.6 million in Q1 2021.
- The 5-year median for Deferred Taxes is -$3.1 million (2021), against an average of $19.4 million.
- Peak annual rise in Deferred Taxes reached 526.14% in 2022, while the deepest fall reached 552.13% in 2022.
- Exelixis' Deferred Taxes stood at $244.1 million in 2018, then tumbled by 90.47% to $23.3 million in 2019, then slumped by 143.52% to -$10.1 million in 2020, then sank by 39.85% to -$14.2 million in 2021, then soared by 526.14% to $60.4 million in 2022.
- Business Quant data shows EXEL's Deferred Taxes at $60.4 million in Q4 2022, $15.3 million in Q3 2022, and -$15.3 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 30, 2022 | 60.36 Mn |
| Jul 1, 2022 | 15.32 Mn |
| Apr 1, 2022 | -15.32 Mn |
| Dec 31, 2021 | -14.16 Mn |
| Oct 1, 2021 | -9.57 Mn |
| Jul 2, 2021 | -26.19 Mn |
| Apr 2, 2021 | 3.39 Mn |
| Jan 1, 2021 | -71.60 Mn |
| Apr 3, 2020 | -10.13 Mn |
| Sep 27, 2019 | 23.27 Mn |
| Jun 28, 2019 | 33.07 Mn |
| Dec 28, 2018 | 244.11 Mn |